Androgenic Alopecia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: AND014 MIFTS: 39	Androgenic Alopecia Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs Download Expand all tables

Sources

Aliases & Classifications for Androgenic Alopecia

MalaCards integrated aliases for Androgenic Alopecia:

Name: Androgenic Alopecia ¹² ¹⁵

Androgenetic Alopecia ¹² ⁷³

Alopecia Androgenetica, Male Pattern Baldness ¹²

Classifications:

MalaCards categories:
Anatomical: Skin diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Diseases of the skin and subcutaneous tissue

Disorders of skin appendages

Androgenic alopecia

External Ids:

Disease Ontology ¹² DOID:0050801

ICD10 ³³ L64

UMLS ⁷³ C0162311

Sources

Summaries for Androgenic Alopecia

MalaCards based summary : Androgenic Alopecia, also known as androgenetic alopecia, is related to alopecia, androgenetic, 1 and alopecia. An important gene associated with Androgenic Alopecia is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Coregulation of Androgen receptor activity and Regulation of Androgen receptor activity. The drugs Finasteride and Minoxidil have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and skin.

Sources

Related Diseases for Androgenic Alopecia

Diseases related to Androgenic Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 57)

#	Related Disease	Score	Top Affiliating Genes
1	alopecia, androgenetic, 1	32.3	AR CYP19A1 SHBG
2	alopecia	30.4	AR EDA2R HR SHBG
3	prostatic hyperplasia, benign	30.1	AR CYP19A1 KLK3
4	polycystic ovary syndrome	30.0	CYP19A1 PRL SHBG
5	hyperandrogenism	29.8	CYP19A1 PRL SHBG
6	47, xxy	10.7	AR SHBG
7	postmenopausal atrophic vaginitis	10.7	AR SHBG
8	nodular prostate	10.6	AR KLK3
9	prostatic acinar adenocarcinoma	10.6	AR KLK3
10	androgen insensitivity syndrome	10.6	AR SHBG
11	hypoactive sexual desire disorder	10.6	CYP19A1 SHBG
12	withdrawal disorder	10.6	AR KLK3
13	premenstrual tension	10.5	PRL SHBG
14	transsexualism	10.5	AR CYP19A1
15	cystitis cystica	10.5	AR KLK3
16	gender identity disorder	10.5	AR CYP19A1
17	estrogen excess	10.5	CYP19A1 SHBG
18	oligospermia	10.5	AR PRL
19	female breast cancer	10.5	AR KLK3
20	gonadal disease	10.5	AR SHBG
21	male reproductive system disease	10.4	AR KLK3
22	mammographic density	10.4	CYP19A1 PRL
23	varicocele	10.4	PRL SHBG
24	prostatic adenoma	10.4	AR KLK3 SHBG
25	acanthosis nigricans	10.3	PRL SHBG
26	male reproductive organ cancer	10.3	AR KLK3 SHBG
27	mccune-albright syndrome	10.3	CYP19A1 PRL
28	hyperprolactinemia	10.3	PRL SHBG
29	androgen insensitivity, partial	10.3	AR CYP19A1 SHBG
30	complete androgen insensitivity syndrome	10.3	AR CYP19A1 SHBG
31	sexual disorder	10.3	KLK3 PRL SHBG
32	impotence	10.2	KLK3 PRL SHBG
33	cryptorchidism, unilateral or bilateral	10.2	AR CYP19A1 SHBG
34	breast disease	10.2	KLK3 PRL SHBG
35	pedophilia	10.2	LPP PRL
36	prostatic hypertrophy	10.2	AR CYP19A1 KLK3
37	pseudohermaphroditism	10.2	AR CYP19A1
38	suppression of tumorigenicity 12	10.2	AR KLK3
39	anovulation	10.2	CYP19A1 PRL SHBG
40	female reproductive system disease	10.2	CYP19A1 PRL SHBG
41	premature ovarian failure 1	10.1	CYP19A1 PRL SHBG
42	ovarian disease	10.1	CYP19A1 PRL SHBG
43	paraphilia disorder	10.1	LPP PRL
44	prostatitis	10.1
45	ductal carcinoma in situ	10.0	AR CYP19A1
46	prostate cancer	9.9
47	alopecia areata	9.9
48	sex differentiation disease	9.8	AR CYP19A1 PRL SHBG
49	amenorrhea	9.8	PRL SHBG
50	diabetes mellitus, noninsulin-dependent	9.7

Graphical network of the top 20 diseases related to Androgenic Alopecia:

Sources

Symptoms & Phenotypes for Androgenic Alopecia

Sources

Drugs & Therapeutics for Androgenic Alopecia

Drugs for Androgenic Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Finasteride

Approved

Phase 4,Phase 3,Phase 1,Phase 2

98319-26-7

57363

Minoxidil

Approved, Investigational

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

38304-91-5

4201

5-alpha Reductase Inhibitors

Phase 4,Phase 3,Phase 1,Phase 2

Antihypertensive Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Hormone Antagonists

Phase 4,Phase 3,Phase 1,Phase 2

Hormones

Phase 4,Phase 3,Phase 1,Phase 2

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 4,Phase 3,Phase 1,Phase 2

Steroid Synthesis Inhibitors

Phase 4,Phase 3,Phase 1,Phase 2

Vasodilator Agents

Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable

Dutasteride

Approved, Investigational

Phase 3,Phase 1

164656-23-9

152945 6918296

Pharmaceutical Solutions

Phase 3,Phase 1,Phase 2,Not Applicable

Nitric Oxide

Approved

Phase 1, Phase 2

10102-43-9

145068 160954

Acetylcholine

Approved

Phase 2

51-84-3

187

Bimatoprost

Approved, Investigational

Phase 2,Phase 1

155206-00-1

5311027

Valproic Acid

Approved, Investigational

Phase 2

99-66-1

3121

Vitamin C

Approved, Nutraceutical

Phase 1, Phase 2,Phase 2

50-81-7

5785 54670067

Maleic acid

Experimental

Phase 1, Phase 2

110-16-7

444266

HIV Protease Inhibitors

Phase 2

protease inhibitors

Phase 2

Proteasome Inhibitors

Phase 2

Adjuvants, Immunologic

Phase 2

Ammonium trichloro(dioxoethylene-O,O'-)tellurate

Phase 2

Anti-Infective Agents

Phase 2,Not Applicable

Antiviral Agents

Phase 2

Protective Agents

Phase 2,Phase 1

Radiation-Protective Agents

Phase 2

Anti-Asthmatic Agents

Phase 1, Phase 2

Antioxidants

Phase 1, Phase 2

Autonomic Agents

Phase 1, Phase 2

Bronchodilator Agents

Phase 1, Phase 2

Endothelium-Dependent Relaxing Factors

Phase 1, Phase 2

Neurotransmitter Agents

Phase 1, Phase 2,Phase 2

Peripheral Nervous System Agents

Phase 1, Phase 2

Respiratory System Agents

Phase 1, Phase 2

Mitogens

Phase 1, Phase 2,Not Applicable

Androgens

Phase 2,Phase 1

abobotulinumtoxinA

Phase 2

Botulinum Toxins

Phase 2

Botulinum Toxins, Type A

Phase 2

Cholinergic Agents

Phase 2

onabotulinumtoxinA

Phase 2

Ophthalmic Solutions

Phase 2

Anticonvulsants

Phase 2

Antimanic Agents

Phase 2

Central Nervous System Depressants

Phase 2

GABA Agents

Phase 2

Psychotropic Drugs

Phase 2

Tranquilizing Agents

Phase 2

Ethanol

Approved

Phase 1,Not Applicable

64-17-5

702

Methyltestosterone

Approved

Phase 1

58-18-4

6010

Interventional clinical trials:

(show top 50) (show all 108)

#	Name	Status	NCT ID	Phase	Drugs
1	Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction	Recruiting	NCT03388840	Phase 4
2	Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia	Active, not recruiting	NCT02999737	Phase 4
3	The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia	Withdrawn	NCT02483195	Phase 4	5% Minoxidil;200mg Spironolactone;5mg Finasteride
4	Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients	Unknown status	NCT01655108	Phase 3	Minoxidil;Saline
5	Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia	Completed	NCT01231607	Phase 3	1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
6	Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia	Completed	NCT00958750	Phase 3	minoxidil
7	A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia	Completed	NCT00441116	Phase 3	Dutasteride 0.5mg oral tablets
8	A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia	Completed	NCT01831791	Phase 3	Dutasteride 0.5 mg
9	Clinical Trial in Females for Female Pattern Hair Loss	Completed	NCT01226459	Phase 3	5% Minoxidil Topical Foam;Vehicle Topical Foam
10	Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia	Completed	NCT02014584	Phase 3	Dutasteride;Placebo
11	Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia	Completed	NCT03004469	Phase 3	P-3074;Finasteride;Vehicle
12	Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111)	Completed	NCT00396175	Phase 3	MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
13	A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss	Completed	NCT00151515	Phase 3	minoxidil
14	Clinical Trial in Females With Female Pattern Hair Loss	Completed	NCT01145625	Phase 3	5% Minoxidil;2% Minoxidil
15	Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss	Completed	NCT01391156	Phase 3	3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
16	Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia	Unknown status	NCT01501617	Phase 1, Phase 2
17	A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia	Unknown status	NCT01643629	Phase 1, Phase 2
18	Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant	Unknown status	NCT01644422	Phase 1, Phase 2
19	Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss	Unknown status	NCT00471510	Phase 2	tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
20	Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women	Unknown status	NCT00418249	Phase 2	AS101
21	Efficacy and Safety Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Androgenetic Alopecia	Unknown status	NCT01650272	Phase 1, Phase 2	5% MInoxidil milky lotion;5% Minoxidil solution
22	Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia	Unknown status	NCT01347957	Phase 1, Phase 2
23	A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing	Completed	NCT02503137	Phase 2	Topical SM04554 solution;Topical Vehicle solution
24	Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia	Completed	NCT01286649	Phase 1, Phase 2
25	A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)	Completed	NCT02275351	Phase 2	SM04554;Vehicle
26	A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia	Completed	NCT02279823	Phase 2	CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
27	Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia	Completed	NCT02865421	Phase 2	stem cells;platelet rich plasma
28	Treatment of Male Pattern Baldness With Botulinum Toxin	Completed	NCT00965640	Phase 2	Botulinum Toxin - A injections
29	Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia	Completed	NCT01319370	Phase 2	Minoxidil;vehicle of 5% Minoxidil topical foam
30	Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss	Completed	NCT02150187	Phase 2
31	Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males	Completed	NCT02781311	Phase 2	setipiprant;placebo
32	Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application	Completed	NCT02280603	Phase 1, Phase 2	DA-4001C;5% minoxidil
33	Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss	Completed	NCT00418730	Phase 2	tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
34	A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)	Completed	NCT01904721	Phase 2	Bimatoprost Solution 1;Bimatoprost Solution 2;Bimatoprost Vehicle
35	Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia	Completed	NCT01325337	Phase 2	bimatoprost Formulation A;bimatoprost Formulation B;bimatoprost Formulation C;bimatoprost vehicle solution;minoxidil 5% solution
36	Topical Bimatoprost Effect on Androgen Dependent Hair Follicles	Completed	NCT02170662	Phase 2	Bimatoprost;Placebo
37	STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia	Completed	NCT02503852	Phase 2
38	A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512)	Completed	NCT01451125	Phase 2
39	A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)	Completed	NCT01669746	Phase 2
40	A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995)	Completed	NCT01451190	Phase 2
41	A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)	Completed	NCT01451177	Phase 2
42	A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)	Completed	NCT01451151	Phase 2
43	A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)	Completed	NCT01451138	Phase 2
44	A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899)	Completed	NCT01451112	Phase 2
45	A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss	Completed	NCT01451099	Phase 2
46	A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013)	Completed	NCT01451073	Phase 2
47	A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)	Completed	NCT01451047	Phase 2
48	A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss	Completed	NCT01451021	Phase 2
49	The Efficacy and Safety of Topical Valproic Acid in Preventing Hair Loss	Completed	NCT01548066	Phase 2	Valproic Acid;Control placebo
50	Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy	Completed	NCT01227993	Phase 1, Phase 2	Finasteride

Search NIH Clinical Center for Androgenic Alopecia

Sources

Genetic Tests for Androgenic Alopecia

Sources

Anatomical Context for Androgenic Alopecia

MalaCards organs/tissues related to Androgenic Alopecia:

⁴¹

Prostate, Testes, Skin, Bone, Heart, Ovary, Endothelial

Sources

Publications for Androgenic Alopecia

Articles related to Androgenic Alopecia:

(show top 50) (show all 506)

#	Title	Authors	Year
1	Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis. ( 29529997 )	Liang W....Dai S.	2018
2	Prescribing Habits for Androgenic Alopecia Among Dermatologists in Spain in 2017: A Cross-Sectional Study. ( 29656764 )	Pindado-Ortega C....VaA+A^-GalvA!n S.	2018
3	Platelet-Rich Plasma for the Treatment of Androgenic Alopecia: A Systematic Review. ( 29954021 )	Chen J.X....Lee L.N.	2018
4	Melatonin vitamin C-based nanovesicles for treatment of androgenic alopecia: Design, characterization and clinical appraisal. ( 29981403 )	Hatem S....Elkheshen S.A.	2018
5	Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia. ( 29443105 )	Gentile P....Cervelli V.	2018
6	Comparison of the Efficacy of Homologous and Autologous Platelet-Rich Plasma (PRP) for Treating Androgenic Alopecia. ( 29101437 )	Ince B....Savaci N.	2018
7	A hypothetical pathogenesis model for androgenic alopecia: clarifying the dihydrotestosterone paradox and rate-limiting recovery factors. ( 29407002 )	English R.S.	2018
8	A proprietary herbal extract against hair loss in androgenetic alopecia and telogen effluvium: a placebo-controlled, single-blind, clinical-instrumental study. ( 29945259 )	Pekmezci E....TA1rkoA9lu M.	2018
9	Quality of Life with Alopecia Areata versus Androgenetic Alopecia Assessed Using Hair Specific Skindex-29. ( 29853767 )	Jun M....Lee W.S.	2018
10	Androgenic alopecia in a postmenopausal Sicilian baroness. ( 29103134 )	BorzA- G....Russo M.	2018
11	A Meta-analysis On Evidence Of Platelet-rich Plasma for Androgenetic Alopecia. ( 29440850 )	Giordano S....Lankinen P.	2018
12	A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. ( 29972712 )	Suchonwanit P....Khunkhet S.	2018
13	Efficacy and Safety of a Low-Level Light Therapy for Androgenetic Alopecia: A 24-Week, Randomized, Double-Blind, Self-Comparison, Sham Device-Controlled Trial. ( 29957664 )	Mai-Yi Fan S....Chiu H.Y.	2018
14	Low-level laser therapy for the treatment of androgenic alopecia: a review. ( 29270707 )	Darwin E....Jimenez J.J.	2018
15	Distinguishing immunohistochemical features of alopecia areata from androgenic alopecia. ( 29790258 )	Kamyab K....Nasimi M.	2018
16	Social selection favours offspring prone to the development of androgenetic alopecia. ( 29254307 )	Goren A....McCoy J.	2017
17	Androgenic alopecia: an entity to consider in adolescence. ( 28754756 )	Rodrigues M....Pereira N.	2017
18	Post-Finasteride Adverse Effects in Male Androgenic Alopecia: A Case Report of Vitiligo. ( 28222425 )	Motofei I.G....Sinescu I.	2017
19	A Comparative Study between the Efficacy and Safety of 5% Minoxidil Solution and 5% Minoxidil Milky Lotion in the Treatment of Male Androgenic Alopecia. ( 29911772 )	Thuangtong R....Suvanasuthi S.	2017
20	Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. ( 28932074 )	Saceda-Corralo D....JaAcn-Olasolo P.	2017
21	Use of low-level laser therapy in treatment of the androgenic alopecia, the first systematic review. ( 29227728 )	Najem I....Chen H.	2017
22	A Spilt Head Study of Efficacy of Placebo versus Platelet-rich Plasma Injections in the Treatment of Androgenic Alopecia. ( 28852294 )	Kachhawa D....Kataiya R.	2017
23	Is there a pathogenetic link between frontal fibrosing alopecia, androgenetic alopecia and fibrosing alopecia in a pattern distribution? ( 29224248 )	Katoulis A.C....Rigopoulos D.	2017
24	A Pilot Study to Evaluate Effectiveness of Botulinum Toxin in Treatment of Androgenetic Alopecia in Males. ( 29403190 )	Singh S....Vasudevan B.	2017
25	Injections of platelet-rich plasma for androgenic alopecia: A systematic review. ( 28676455 )	Picard F....Meningaud J.P.	2017
26	Comparison of the effects of 665 nm low level diode Laser Hat versus and a combination of 665 nm and 808nm low level diode Laser Scanner of hair growth in androgenic alopecia. ( 28513251 )	Barikbin B....Akbarpour S.	2017
27	Conventional and novel stem cell based therapies for androgenic alopecia. ( 28979149 )	Talavera-Adame D....Newman N.	2017
28	Systematic review of low-level laser therapy for adult androgenic alopecia. ( 29286826 )	Delaney S.W....Zhang P.	2017
29	Hematuria and Hematospermia Associated with the Use of Finasteride for the Treatment of Androgenic Alopecia: A Case Report. ( 29090364 )	Fouda A.M....Bazeed A.M.	2017
30	Higher plasma leptin is associated with higher risk of androgenetic alopecia in men. ( 28423238 )	Yang C.C....Tsai Y.S.	2017
31	Digit-Length Ratios (2D:4D) as a Phenotypic Indicator of in Utero Androgen Exposure is Not Prognostic for Androgenic Alopecia: a Descriptive-Analytic Study of 1200 Iranian Men. ( 27942367 )	Feily A....Ramirez-Fort M.K.	2016
32	Stem cell therapy as a novel therapeutic intervention for resistant cases of alopecia areata and androgenetic alopecia. ( 27553744 )	Ibrahim Z.A....Salem M.L.	2016
33	Commentary on A New Subtype of Lichen Planopilaris Affecting Vellus Hairs and Clinically Mimicking Androgenetic Alopecia. ( 27661431 )	Stough D.	2016
34	Psychosocial Impairment as a Possible Cause of Sexual Dysfunction among Young Men with Mild Androgenetic Alopecia: A Cross-sectional Crowdsourcing Web-based Study. ( 27149130 )	Molina-Leyva A....Jimenez-Moleon J.J.	2016
35	Meta-analysis of efficacy of platelet-rich plasma therapy for androgenetic alopecia. ( 27152474 )	Gupta A.K....Carviel J.L.	2016
36	Finasteride adverse effects in subjects with androgenic alopecia: A possible therapeutic approach according to the lateralization process of the brain. ( 27046152 )	Motofei I.G....Paunica S.	2016
37	Benign prostatic hyperplasia, metabolic syndrome and androgenic alopecia: Is there a possible relationship? ( 27489744 )	Agamia N.F....El-Abd A.	2016
38	The role of oxidative stress in early-onset androgenetic alopecia. ( 27987270 )	Kaya Erdogan H....Alatas O.	2016
39	Are 2D:4D finger-length ratios an indicator of androgenetic alopecia in males? ( 27192513 )	Bilgic A.9....TuA9rul Z.A.	2016
40	Efficacy and Safety of Minoxidil 5% Foam in Combination With a Botanical Hair Solution in Men With Androgenic Alopecia. ( 27050695 )	Keaney T.C....Meckfessel M.H.	2016
41	Efficacy of Activated 3X Platelet-Rich Plasma in the Treatment of Androgenic Alopecia. ( 28296871 )	James R....Deb K.	2016
42	A Mechanistic Model of Platelet-Rich Plasma Treatment for Androgenetic Alopecia. ( 27631460 )	Gupta A.K....Carviel J.	2016
43	Relation of urinary stone disease with androgenetic alopecia and serum testosterone levels. ( 27155830 )	Polat E.C....Ozbek E.	2016
44	Efficacy and Safety of Minoxidil 2% Solution in Combination With a Botanical Hair Solution in Women With Female Pattern Hair Loss/Androgenic Alopecia. ( 27050694 )	McMichael A....Meckfessel M.H.	2016
45	[Association of eight single nucleotide polymorphisms of chromosomes 20 and X with androgenetic alopecia among ethnic Han Chinese from Yunnan]. ( 27264827 )	Ye M....Cheng B.	2016
46	Identification of a new plant extract for androgenic alopecia treatment using a non-radioactive human hair dermal papilla cell-based assay. ( 26796631 )	Jain R....De-Eknamkul W.	2016
47	Assessment of vitamin D receptors in alopecia areata and androgenetic alopecia. ( 27151518 )	Fawzi M.M....Shaker O.G.	2016
48	Platelet-Rich Plasma in Androgenic Alopecia: Indications, Technique, and Potential Benefits. ( 27918883 )	Ferneini E.M....Ferneini M.V.	2016
49	Differential Expression between Human Dermal Papilla Cells from Balding and Non-Balding Scalps Reveals New Candidate Genes for Androgenetic Alopecia. ( 27060448 )	Chew E.G....Hillmer A.M.	2016
50	Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia. ( 28024997 )	Cauci S....Trombetta C.	2016

Sources

Genes for Androgenic Alopecia

Genes related to Androgenic Alopecia (0 elite genes):

(show all 11)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	SHBG	Sex Hormone Binding Globulin	Protein Coding	23.8	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	AR	Androgen Receptor	Protein Coding	23.67	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	EFNA3	Ephrin A3	Protein Coding	21.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	KLK3	Kallikrein Related Peptidase 3	Protein Coding	21.16	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	PRL	Prolactin	Protein Coding	20.95	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	19.78	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	EDA2R	Ectodysplasin A2 Receptor	Protein Coding	17.69	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
8	HR	HR, Lysine Demethylase And Nuclear Receptor Corepressor	Protein Coding	16.7	GeneCards inferred via : Publications (show sections)
9	LPP	LIM Domain Containing Preferred Translocation Partner In Lipoma	Protein Coding	15.89	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
10	GGN	Gametogenetin	Protein Coding	15.71	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
11	PPP1R3C	Protein Phosphatase 1 Regulatory Subunit 3C	Protein Coding	15.32	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)

Sources

Variations for Androgenic Alopecia

Sources

Expression for Androgenic Alopecia

Search GEO for disease gene expression data for Androgenic Alopecia.

Sources

Pathways for Androgenic Alopecia

Pathways related to Androgenic Alopecia according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Coregulation of Androgen receptor activity ¹	11.08	AR KLK3
2	Regulation of Androgen receptor activity ¹	10.96	AR KLK3
3	FOXA1 transcription factor network ¹ Show member pathways FOXA transcription factor networks ¹	10.82	AR KLK3
4	Transcription_Role of VDR in regulation of genes involved in osteoporosis ²²	10.61	AR CYP19A1
5	Nongenotropic Androgen signaling ¹	9.88	AR SHBG

Sources

GO Terms for Androgenic Alopecia

Biological processes related to Androgenic Alopecia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mammary gland development	GO:0030879	9.26	CYP19A1 PRL
2	regulation of systemic arterial blood pressure	GO:0003073	9.16	AR KLK3
3	negative regulation of angiogenesis	GO:0016525	9.13	EFNA3 KLK3 PRL
4	prostate gland growth	GO:0060736	8.62	AR CYP19A1

Molecular functions related to Androgenic Alopecia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	steroid binding	GO:0005496	8.96	AR SHBG
2	androgen binding	GO:0005497	8.62	AR SHBG

Sources

Sources for Androgenic Alopecia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia